Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tu...

Full description

Bibliographic Details
Main Authors: Gabriela Jiménez-Valerio, Mar Martínez-Lozano, Nicklas Bassani, August Vidal, María Ochoa-de-Olza, Cristina Suárez, Xavier García-del-Muro, Joan Carles, Francesc Viñals, Mariona Graupera, Stefano Indraccolo, Oriol Casanovas
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124716304284

Internet

http://www.sciencedirect.com/science/article/pii/S2211124716304284

Similar Items